Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CinnaGen pembrolizumab versus Keytruda in metastatic NSCLC
IRCT20150303021315N29Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by CinnaGen. Primary endpoint: Progression-free survival. Started Apr 2022; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on IRCT20150303021315N29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N29.